BACKGROUND: Current treatment guidelines recommend adjuvant @entity8449 after resection of @entity1636 with high-risk features (eg, @entity5 rupture, positive margins, positive lymph nodes, high grade, elevated mitotic index, and advanced stage). Limited data exist on the outcomes associated with these practice guidelines. STUDY DESIGN: @entity1 who underwent resection of @entity1636 from 1993 to 2014 at the 13 academic institutions of the US @entity1636 Group were included. Factors associated with @entity8449 administration were determined. Primary end points were @entity1349 ( @entity1349 ) and @entity1349 ( @entity1349 ). RESULTS: Of 207 @entity1 , 88 (43%) received adjuvant @entity8449 . Receipt of @entity8449 was associated with hormonal secretion (58% vs 32%; p  = 0.001), advanced @entity2802 stage (stage IV: 42% vs 23%; p  = 0.021), adjuvant chemotherapy (37% vs 5%; p < 0.001), and adjuvant radiation (17% vs 5%; p  = 0.01), but was not associated with @entity5 rupture, margin status, or N-stage. Median follow-up was 44 months. Adjuvant @entity8449 was associated with decreased @entity1349 (10.0 vs 27.9 months; p  = 0.007) and @entity1349 (31.7 vs 58.9 months; p  = 0.006). On multivariable analysis, @entity8449 was not independently associated with @entity1349 or @entity1349 , and margin status, advanced @entity2802 stage, and receipt of chemotherapy were associated with survival. After excluding all @entity1 who received chemotherapy, adjuvant @entity8449 remained associated with decreased @entity1349 and similar @entity1349 ; multivariable analyses again showed no association with recurrence or survival. Stage-specific analyses in both cohorts revealed no association between adjuvant @entity8449 and improved @entity1349 or @entity1349 . CONCLUSIONS: When accounting for @entity5 and treatment-related factors, adjuvant @entity8449 after resection of @entity1636 is not associated with improved @entity1349 or @entity1349 . Current guidelines should be revisited and prospective trials are needed.

Outcomes of Adjuvant @entity8449 after Resection of XXXX : A 13-Institution Study by the US @entity1636 Group.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity8449 :: ('MESH:D008939', 'Chemical') :: ['mitotane'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'stage and adverse tumor'] @entity2802 :: ('10178', 'Gene') :: ['TNM'] @entity1636 :: ('MESH:D018268', 'Disease') :: ['Adrenocortical Carcinoma', 'adrenocortical carcinoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'RFS', 'recurrence-free survival', 'overall survival']
@entity1636 :: (MESH:D018268,Disease) :: ['Adrenocortical Carcinoma']
